COSENTYX (Novartis Pharmaceuticals Australia Pty Ltd)
Product name
COSENTYX
Date registered
Evaluation commenced
Decision date
Approval time
204 (255 working days)
Active ingredients
secukinumab (rch)
Registration type
EOI
Indication
Plaque psoriasis
COSENTYX (powder for injection; solution for injection) is now also indicated for the treatment of moderate to severe plaque psoriasis in patients 6 years and older who are candidates for systemic therapy or phototherapy.